Navican Genomics is a precision medicine company focused on comprehensive cancer care. It offers testing and treatment options for actionable gene mutations, as well as next-generation sequencing. Its TheraMap solution enables users to leverage precision genomics and clinical analytics to improve patient outcomes.
Navican will use the new funds to commercialize and expand its cancer care offerings, including the TheraMap solution.
“Innovation is a top priority at Intermountain Healthcare,” said Marc Harrison, MD, president and CEO of Intermountain Healthcare. “As we develop incredible advancements that will improve healthcare outcomes, we are excited to partner with companies such as Navican to serve patients and communities around the world.”
Intermountain Healthcare led the financing round.
More articles on health IT:
VA’s most expensive task? Modernizing IT, says Shulkin
IBM: 5 insights on Watson’s oncology performance
Medicare would save $63M annually with HIEs, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
